Rare Disease Clinical Trial
Official title:
Idiopathic Diseases of Man (IDIOM)
This research is being done to learn more about possible genetic causes of currently undiagnosed conditions, and to find out how the development of new technologies, such as DNA sequencing, can increase knowledge of the role genetic variants play in disorders and possibly how genetic variants may help de-termine the best treatment options. The recent development of new technologies has increased our ability to understand how genetic mutations are associated with disease. Using these technologies to find the genetic variants responsible for rare diseases is a rapidly growing field and has already begun to transform the way conditions with unknown causes are diagnosed and treated. Hypothesis: Identification of new genomic variants associated with idiopathic diseases and/or diseases of unknown etiology will advance medical knowledge about rare and common diseases.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05203250 -
Longitudinal Registry Including Patients Treated With Heavy Particles
|
||
| Recruiting |
NCT02938793 -
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
|
Phase 2 |